FIELD: medicine.SUBSTANCE: disclosed are versions of using a purified population of germination-competent bacterial spores for treating or preventing or reducing the severity of at least one symptom of gastrointestinal dysbiosis associated with Clostridium difficile, including a recurrent C.difficile infection, or ulcerative colitis in a mammalian recipient, as well as versions of a therapeutic composition containing an effective amount of a purified population of germination-competent bacterial spores. Germination-competent bacterial spores can be obtained by the following steps: a) providing a fecal material from a mammalian donor, and b) carrying out ethanol treatment or heat treatment of the fecal material, resulting in a population of germination-capable bacterial spores. From said purified population, a pathogenic material is substantially eliminated at a detectable level, or the pathogenic material is substantially free of pathogenic activity or has a reduced level of pathogenic activity, where said pathogenic material is optionally selected from a group consisting of a virus, a bacterium, a eukaryotic parasite, a helminth, a phage, a mycoplasma, toxoplasma and a fungus. Spores contain at least two kinds of bacteria comprising nucleic acid sequences that are at least 97% identical to the nucleic acid sequences selected from the group consisting of SEQ ID NO. 6, SEQ ID NO. 383, SEQ ID NO. 381, SEQ ID NO. 572, SEQ ID NO. 601, SEQ ID NO. 652, SEQ ID NO. 659, SEQ ID NO. 673, SEQ ID NO. 674, SEQ ID NO. 774, SEQ ID NO. 839, SEQ ID NO. 845, SEQ ID NO. 847, SEQ ID NO. 848, SEQ ID NO. 856, SEQ ID NO. 874, SEQ ID NO. 880, SEQ ID NO. 886, SEQ ID NO. 1049, SEQ ID NO. 1591, SEQ ID NO. 1655, SEQ ID NO. 1657, SEQ ID NO. 1670 and SEQ ID NO. 1896.EFFECT: group of inventions provides effective prevention, control and treatment of diseases, disorders and conditions of the gastrointestinal tract associated with Clostridium difficile, and ensuring the healthy functioning of the d
